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Effects of prednisone withdrawal on the new metabolic triad in Cardiovascular disease is the most common cause of
cyclosporine-treated kidney transplant patients. death after renal transplantation [1–4]. One of the major
Background. Cardiovascular disease is a major cause of mor- metabolic risk factors for the development of cardiovas-bidity and mortality after renal transplantation. Prednisone (Pred)
cular disease is hyperlipidemia, which is a well-recog-maintenance therapy is associated with risk factors for athero-
nized complication in renal transplant recipients (RTX)sclerosis. Therefore, we were interested in quantifying the effects
of Pred withdrawal on body weight and waist circumference [5–10]. Although several factors such as weight gain re-
as well as on metabolic markers of coronary heart disease risk. sulting from an increase in caloric intake, steroid-induced
Methods. Twenty-six cyclosporine-treated renal transplant insulin resistance, hyperinsulinemia and diabetes, kidneypatients (13 men and 13 women) were evaluated before and
graft dysfunction and concomitant antihypertensive med-after at least 11 months (16 2.9 months) of Pred withdrawal.
ications have been documented to contribute to the ex-A complete fasting lipoprotein-lipid profile as well as anthropo-
metric measurements were obtained from each patient. pression of hyperlipidemia in RTX, there is evidence for
Results. Pred withdrawal was associated with a 6.0% reduc- a major contribution of the immunosuppressive therapy
tion of body weight (4.34  5.40 kg; P  0.05) and with a
required in these patients [11–14].7.7% decrease in waist girth (7.13  5.75 cm; P  0.005) in
After transplantation, elevated levels of serum totalwomen, whereas no change in these variables were observed
in men. In both genders, plasma low-density lipoprotein (LDL) cholesterol, low-density lipoprotein (LDL) cholesterol,
cholesterol and triglyceride concentrations were unaffected by apolipoprotein (apo) B and triglycerides (TG) have been
Pred withdrawal, whereas plasma high-density lipoprotein (HDL) related to the combined use of cyclosporine (CsA) and
cholesterol levels decreased by 14.0% in women (0.22 0.22
prednisone (Pred) [7, 8, 15–20]. It is generally believedmmol/L; P  0.005) and 22.0% in men (0.36  0.28 mmol/L;
that CsA has adverse effects on the lipoprotein-lipid pro-P  0.005). Pred withdrawal was associated with a significant
reduction in plasma apolipoprotein B concentrations in both file mainly through increases in total cholesterol, LDL
women (0.28  0.15 g/L; 24.6%; P  0.0001) and men cholesterol and apo B levels. Addition of Pred appears
(0.22 0.19 g/L;20.5%; P 0.005). A significant reduction to induce a further increase of total cholesterol, whichin fasting insulin was observed in both women (27.8  27.9
mainly results from the elevation of high-density lipopro-pmol/L; 25.3%; P  0.005) and men (25.0  32.8 pmol/L;
tein (HDL) cholesterol and TG concentrations [15–17,21.4%; P  0.05), whereas the LDL peak particle size was
unaffected by Pred withdrawal. 20, 21]. However, the respective contributions of these
Conclusions. Pred withdrawal modifies several anthropo- drugs to the altered metabolic risk factor profile remains
metric and metabolic cardiovascular risk factors in renal trans- uncertain and the withdrawal of steroids in CsA-treatedplant patients. Furthermore, female patients may derive further
patients has generated equivocal results. The reportedbenefits of Pred withdrawal resulting from the concomitant
loss of body weight and abdominal fat. benefits of steroid withdrawal in RTX included improved
hypertension [22, 23], reduced cholesterol or LDL cho-
lesterol and apo B levels [24–26], and enhanced glycemic
control in diabetic patients [27, 28]. Moreover, after with-
drawal, fewer antihypertensive drugs were necessary, fewer
Key words: immunosuppression withdrawal, body weight post-trans-
patients needed cholesterol-lowering drugs, and the fre-plant, lipoprotein-lipid profile, atherogenic metabolic triad, hyperlipid-
emia, cardiovascular disease. quency of type 2 diabetes was reduced [28]. One study
has suggested beneficial effects of Pred on blood pres-Received for publication September 21, 2001
sure, cholesterol levels and glycemia as well as on theand in revised form May 23, 2002
Accepted for publication May 29, 2002 occurrence of these metabolic alterations [28]. In the
other hand, another study has reported potentially dele- 2002 by the International Society of Nephrology
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terious effects of tapering corticosteroids as suggested tive antibodies had to be below 80%. Furthermore, to
be eligible for the study, the transplantation procedureby a large fall in HDL cholesterol levels and increases
in TG concentrations [29]. had to be performed at least six months prior to the
tapering protocol of Pred and patients had to show noFurthermore, weight gain also has been reported in re-
nal transplant patients under corticosteroid therapy [14]. signs of allograft rejection. After meeting all of these
inclusion criteria, patients were invited to participate toObesity, especially visceral obesity, is associated with an
atherogenic fasting lipoprotein phenotype, which includes the study on a voluntary basis. The Pred was withdrawn
according to the CTS protocol. Patients were on a doublehypertriglyceridemia, elevated apo B levels, reduced
HDL cholesterol concentrations and an increased pro- Pred and CsA therapy. At the time of the drug tapering,
most of patients were on 10 mg or less of Pred. This drugportion of small, dense LDL particles [30–32]. This ath-
erogenic fasting lipoprotein phenotype of visceral obesity was withdrawn progressively until complete withdrawal
over a six-month period. Serum creatinine and CsA lev-has been reported to be a feature of the insulin resistance
syndrome, which is associated also with impaired insulin els were measured every two weeks and 24-hour urinary
samples were collected every month during the with-action and an elevated blood pressure [33, 34]. Increasing
evidence suggests that the measurement and interpreta- drawal period. Serum CsA levels remained stable (150
to 250 g/L) throughout the tapering period and for thetion of some elements of this syndrome, which we have
described as the atherogenic metabolic triad of uncon- three following months. After the six-month withdrawal
period, serum creatinine and CsA levels continued to beventional risk factors (hyperinsulinemia, elevated apo B
and small, dense LDL), may further improve the discrim- evaluated every two weeks for a period of two months,
whereas the 24-hour urinary samples were collected everyination of individuals at high risk for cardiovascular dis-
ease [35]. month for an additional four-month period. Patients with
steroid-induced diabetes and with type 1 diabetes alsoSince the treatment of RTX with immunosuppressive
drugs, especially corticosteroids, affects body weight, in- were eligible to participate in the study in order to verify
the potential effect of steroid withdrawal on their glucosesulinemia and the plasma lipoprotein-lipid profile, it was
relevant to verify whether the withdrawal of corticoste- control. Older patients were favored because they are at
lower immunologic risk than young patients and becauseroids may affect components of the insulin resistance
syndrome and more specifically, the new atherogenic nephrologists felt that these older patients were at higher
risk of side effects of steroids. After meeting all thesemetabolic triad: elevated insulin and apo B, and small
dense LDL phenotype. Therefore, the objective of the criteria inclusion, patients were invited to participate to
the study on a voluntary basis. One man and two womenpresent study was to quantify the effects of Pred with-
drawal on morphometric and metabolic risk factors for were current smokers. Ex-smokers who had stopped
smoking for more than one year were considered to becardiovascular disease in a sample of 26 RTX.
non-smokers. Three women and two men were diagnosed
as type 2 diabetic patients. Subjects with elevated choles-
METHODS
terol levels received HMG CoA-reductase inhibitors (8
Patients men and 5 women) for whom doses remained stable for
the entire study period. Regarding the intake of HMGTwenty-six RTX (13 men and 13 women), treated with
CsA and Pred for immunosuppression, were followed in CoA-reductase inhibitors the year before the instigation
of the study, three patients had started hypolipidemicthe present study. Subjects were first evaluated three to
four years after renal transplantation and re-evaluated drugs, one had increased the dose whereas another had
decreased the dose. Finally, one patient was switchedfor cardiovascular risk factors following Pred withdrawal
of about 16 months. All the kidney allografts came from from one statin to another. Patients with hypertension
were usually treated with angiotensin-converting enzymecadavers. Neither acute allograft rejection nor significant
leukopenia was observed following Pred withdrawal (ACE) inhibitors (10 men and 3 women) and/or diuretics
(4 men and 7 women). This study was approved by theamong these kidney transplant patients. However, al-
most half of the patients presented arthralgic pains that Medical Ethics Committee of the L’Hoˆtel-Dieu de Que´-
bec. Informed written consent was obtained from alldecreased with time. There was no wash-in period before
the initiation of this study, but the results indicated that participants.
there was no significant change in the investigated pa-
Measurement of body fatness and blood pressurerameters for the whole year prior to the start of the
study. This study was the non-randomized arm of the Col- Body weight, height and waist circumferences were
measured by following the procedures recommended atlaborative Transplant Study (CTS) [36]. To be included
in the study, all patients had to have an excellent and the Airlie conference [37]. More specifically, the mea-
surement of waist circumference was performed at thestable renal function (creatinine 180 mol/L), no sig-
nificant proteinuria (300 mg/day) and the panel of reac- narrowest part of the torso located between the lower
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rib and the iliac crest while the subjects were standing, Liquid Scintillation Counter (Pharmacia, Turku, Fin-
land) for two minutes with a counting error of less thanafter a moderate expiration. Blood pressure was mea-
sured with a standardized sphygmomanometer after at 1%. CETP activity was expressed as the percentage of
radioactivity transferred from HDL3 to the acceptor frac-least five minutes with the patients in a supine position.
tion over 16 hours of incubation. All assays were per-
Laboratory methods formed as duplicates and were re-run when the coeffi-
cient of variation within duplicates exceeded 4.5%.Venous blood samples were obtained after a 12-hour
overnight fast. Cholesterol and TG levels were measured
Assessment of LDL size by gradientby enzymatic methods (International Laboratory Co.,
gel electrophoresisLexington, MA, USA), creatinine (serum and urine) was
determined by a colorimetric assay using alcalin picrate Non-denaturating 2 to 16% polyacrylamide gradient
gel electrophoresis (PAGG) was performed on whole(Chiron, Cergy Pontoise, France) and urinary proteins
were measured using the pyrogallol red assay (EMS Inc., plasma kept at80C before use, according to the proce-
dure described by Krauss and Burke [42] and McNamaraExton, PA, USA). All those assays were performed using
a ILAB 900 analyzer (Beckman Coulter, Chaska, MN, et al [43]. Gels were cast in our laboratory using acryl-
amide and bis-acrylamide (30:0.8) obtained from Bio-USA). HDL cholesterol was determined by precipitation
of apo B-containing lipoproteins using magnesium phos- Rad (Hercules, CA, USA). A volume of 7.5L of plasma
samples was applied on lanes in a final concentration ofphotungstate (Fisher Scientific, Nepean, ON, CAN). LDL
cholesterol was calculated according to the Friedewald 20% sucrose and 0.25% bromophenol blue. Electropho-
resis was performed in a refrigerated cell (10 to 15C)formula if TG concentrations were below 4.5 mmol/L
[38]. Apo B was determined by turbidimetry using hu- for a pre-run of 15 minutes at 125 V and for the entry
of samples into stacking at 70 V, followed by migrationman polyclonal antibodies (Atlantic Antibodies, Stillwa-
ter, MN, USA). Fasting insulinemia was determined in at 200 V for 12 to 16 hours and finally at 400 V for 2 to 4
duplicates in frozen sera samples using a human insulin hours. Gels were stained for lipids overnight with Sudan
specific radioimmunoassay (RIA) kit (Linco Research black (Lipostain, Paragon electrophoresis system; Beck-
Inc., St. Louis, MO, USA), showing little cross-reactivity man, Montre´al, Canada) in 55% ethanol. Gels were de-
(0.2%) with human pro-insulin, as previously described stained in a 45% ethanol solution, and the original gel
[39]. Coefficients of variation for cholesterol, TG, HDL, size was restored in a 9% acetic acid, 20% methanol
apo B and fasting insulin levels were 2.5%, 4%, solution. A plasma pool was used as an internal standard.
6.5%, 4.5% and 7.5%, respectively. Gels were analyzed using an optical densitometric image
analyzer (Bio-Image Visage 110) coupled to a SPARC
Assessment of cholesteryl ester transfer Station 2 Sun computer (Millipore, Ville St-Laurent,
protein activity Canada) and using GEL 1D software. LDL peak particle
Cholesteryl ester transfer protein (CETP) activity was size was obtained with the migration of standards of
measured by an isotopic transfer assay using diluted known diameter, such as ferritin (122 A˚), thyroglobulin
plasma with exogenous substrates [40, 41]. Recent stud- (170 A˚), 380 A˚ latex beads (Duke Scientific Corporation,
ies have suggested that the assessment of CETP activity Palo Alto, CA, USA), and plasma standards of known
approximates CETP mass [40, 41]. diameters. Inter- and intra-assay coefficients of variation
Plasma CETP activity was measured as the relative were 2% and 1.5%, respectively.
transfer of total tritiated cholesteryl ester (3H-CE) from
Statistical analysesHDL3 (donor lipoprotein) to an acceptor lipoprotein
fraction (d  1.019 to 1.063 g/mL). Donor and acceptor Student paired t tests were performed to test the sig-
lipoproteins were prepared from fresh plasma of normo- nificance of changes in variables measured over the aver-
lipidemic volunteers. The CETP assay consisted of 50L age 16-month period (range 11 to 22 months) of steroid
of radiolabeled HDL3, 200 L of the acceptor fraction withdrawal. Pearson correlation coefficients were used
and 10 L of plasma in a final volume of 270 L, incu- to quantify the associations among variables (1) at base-
bated for 16 hours at 37C. Tris buffer was used as blank. line and at follow-up and (2) between changes observed
Internal standards were included in each assay. The reac- for variables studied over the 16-month period. All statis-
tion was stopped by transferring the tubes to ice for 15 tical analyses were performed on the SAS package (SAS
minutes. Donor and acceptor lipoproteins were sepa- Institute, Cary, NC, USA).
rated by precipitation of apo B-containing lipoproteins
with heparin (6%)/MnCl2 (2.1 mol/L). Aliquots of the
RESULTSsupernatant (200 L) were transferred to plastic count-
Baseline clinical characteristics of the patients areing vials with liquid scintillant (Ecolite, ICN, Costa Mesa,
CA, USA). The samples were counted in Wallac 1049 shown in Table 1. All patients were under CsA and Pred
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Table 1. Baseline clinical characteristics of 13 female and 13 male The effects of steroids withdrawal on the components
renal transplant patients before prednisone withdrawal
of the new atherogenic metabolic triad are presented in
Variables Women Men Figure 1. Significant and substantial decreases in plasma
Age years 57.65.84 57.211.1 insulin (27.8 27.9 pmol/L,25.3%, P 0.005;25.0
Time since transplantation years 4.642.91 3.722.46 32.8 pmol/L, 21.4%; P  0.05 for women and men,
Prednisone/cyclosporine 13/13 13/13
respectively) and apo B (0.28 0.15 g/L,24.6%, PPrednisone mg/day 7.112.72 9.212.67
Cyclosporine mg/day 178.561.5 209.670.4 0.0001; 0.22  0.19 g/L, 20.5%, P  0.005) levels
Cyclosporine lg/L 216.839.4 222.535.1 were observed in both genders. No significant change in
Diabetes 3 2
LDL peak particle diameter was noted.Menopause/HRT 13/3 N/A
Smokers 2 1 We then examined whether weight loss was associated
Blood pressure mm Hg with changes in insulin and apo B concentrations. Pear-
Systolic 151.212.9 138.717.7
son’s correlation coefficients were not significant betweenDiastolic 88.88.20 84.29.18
Creatinine lmol/L 97.724.8 114.717.7 weight loss and changes in plasma insulin and apo B levels
Creatinine clearance mL/sec/1.73 m*2 1.200.33 1.150.52 in both genders (data not shown).
Proteinuria g/day 0.110.09 0.160.17
As fasting TG concentration is the best predictor of
HRT is hormone replacement therapy. LDL peak particle size, Figure 2 illustrates the relation-
ships between these two variables as well as the correla-
tion between their changes in the overall study sample.
Significant associations were found between plasma TGtherapy at the beginning of the study. Three women and
and LDL size before (r  0.62, P  0.0007) and aftertwo men were diagnosed with type 2 diabetes and all
(r  0.62, P  0.0008) Pred withdrawal. Furthermore,women were postmenopausal at the time of the investi-
changes in LDL peak particle size were significantly cor-gation. All patients were characterized by a good renal
related with changes in plasma TG levels (r  0.51,graft function (plasma creatinine 200 mol/L and pro-
P  0.008). Thus, as no significant change in TG levelsteinuria 1.5 g/day).
were noted following Pred withdrawal, these results sug-Table 2 shows the physical characteristics of the pa-
gest that the lack of increase in LDL size in response totients before and after Pred withdrawal. A significant
steroid tapering was due to the absence of overall changebody weight loss (4.34  5.40 kg, 6.04%, P  0.05)
in fasting TG concentration in response to the protocol.was noted in women following Pred withdrawal whereas
no change was observed in men. Accordingly, waist cir-
cumference and BMI were also significantly reduced in DISCUSSION
women but not in men in response to tapering the ste- It is well known that the incidence of cardiovascular
roids (7.13  5.75 cm, 7.73%, P  0.005; 1.72  diseases is high after renal transplantation and the factors
2.10 kg/m2, 6.04%, P  0.05 for waist girth and BMI, responsible for atherosclerosis in RTX are not well un-
respectively). derstood. Many factors known to increase the risk of
The effects of Pred withdrawal on the plasma lipopro- cardiovascular disease are commonly found in RTX.
tein-lipid profile are shown in Table 3. In women, the Among those, hyperlipidemia is a common metabolic
only significant change was for HDL cholesterol concen- alteration after renal transplantation [6, 7, 9, 10].
trations that were reduced by 14% (0.22  0.22, P  The pathogenesis of hyperlipidemia in renal transplant
0.005) after withdrawal of steroids. Decreased HDL cho- patients is also poorly defined. In this regard, it has been
lesterol concentrations were found also in men (0.36 reported that immunosuppressive therapy may be one
0.28, 22.0%, P  0.005) and this reduction in HDL of the possible causes of the atherogenic dyslipidemia
cholesterol was greater in men than in women. Thus, noted after renal transplantation, since it has an adverse
despite a significant reduction in total cholesterol levels effect on lipid metabolism [7–9]. However, there is dis-
in men (0.56  0.83, 9.74%, P  0.05), the marked agreement on the nature and magnitude of lipoprotein
reduction in HDL cholesterol led to an increase in the changes induced by these drugs. In the present study, it
cholesterol/HDL cholesterol ratio in men (0.54 0.74, was therefore of particular interest to determine whether
18.3%, P  0.05). Despite the fall in HDL cholesterol Pred withdrawal may improve the plasma lipoprotein-
concentrations, it is important to point out that levels lipid profile and more specifically, the components of
after the withdrawal of steroids remained above 1.4 the new atherogenic metabolic triad (insulin and apo B
mmol/L in women and 1.1 mmol/L in men, values that levels and small, dense LDL) in renal transplant subjects
correspond to the 50e percentile values of their respective in whom Pred was stopped for at least 11 months.
age and gender [44]. Plasma CETP activity was signifi- It is well documented that corticosteroid hormones
cantly increased in both genders after Pred tapering (P create an insulin-resistant state leading to hyperinsulin-
emia [45, 46]. In the present study, fasting insulin levels0.05).
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Table 2. Physical characteristics of 13 female and 13 male renal transplant patients before and after prednisone withdrawal
Absolute Relative
Variables Before After difference difference % P value
Women
Weight kg 63.714.5 59.311.1 4.345.40 6.04 0.05
Waist girtha cm 88.515.6 81.313.4 7.135.75 7.73 0.005
BMI kg/m2 26.35.78 24.65.06 1.722.10 6.04 0.05
Men
Weight kg 73.16.91 73.48.79 0.383.66 0.42 NS
Waist girtha cm 94.39.02 94.011.8 0.466.99 0.48 NS
BMI kg/m2 25.92.68 26.03.42 0.141.32 0.42 NS
a 12 subjects; BMI is body mass index
Table 3. Fasting plasma lipoprotein-lipid profile as well as plasma CETP activity of the 13 female and 13 male renal transplant patients
before and after prednisone withdrawal
Absolute Relative
Variables Before After difference difference % P value
Women
Cholesterol mmol/L 5.910.89 5.500.90 0.400.73 6.94 NS
LDL chol mmol/L 3.310.78 3.110.73 0.200.74 3.64 NS
HDL chol mmol/L 1.660.54 1.440.58 0.220.22 14.0 0.005
Chol/HDL chol ratio 3.841.13 4.191.24 0.350.82 10.8 NS
Triglycerides mmol/L 2.080.94 2.130.95 0.050.70 11.2 NS
CETP activitya 19.96.86 26.67.89 6.727.30 46.3 0.05
Men
Cholesterol mmol/L 5.330.78 4.770.89 0.560.83 9.74 0.05
LDL chol mmol/L 3.060.88 2.870.76 0.190.67 2.63 NS
HDL chol mmol/L 1.520.37 1.160.24 0.360.28 22.0 0.005
Chol/HDL chol ratio 3.700.96 4.240.95 0.540.74 18.3 0.05
Triglycerides mmol/L 1.670.64 1.670.50 0.0040.57 8.33 NS
CETP activitya 17.56.93 22.26.84 4.634.79 46.3 0.05
Data are means  SD.
a 3H-CE transferred/16 hours
were significantly reduced after Pred tapering in both concentrations [7–9, 15–20], metabolic changes that con-
tribute to an increased IHD risk. In accordance withgenders. Results of the present study provide further
support to the notion that there is a deleterious effect these previous findings, apo B concentrations in the pres-
ent study were significantly reduced after Pred with-of Pred on fasting insulin levels. There has been an in-
creasing interest in insulin and insulin resistance as po- drawal in both genders. Reductions of apo B levels also
have been reported in diabetic RTX following Pred with-tential major risk factors for ischemic heart disease
(IHD) and as central components of a plurimetabolic drawal [25]. Moreover, only among men of the study
were lower total cholesterol levels observed followingsyndrome that may contribute to the atherosclerotic pro-
cess [34]. Hyperinsulinemia has been related to IHD risk Pred withdrawal. Results of the present study confirm
previous observations suggesting that withdrawal of ste-in at least five prospective studies in men [39, 47–50].
However, whether there is an independent association roid therapy is accompanied by a decrease in total choles-
terol concentrations [25, 26, 53, 54]. On the other hand,between plasma insulin levels and IHD after control for
the concomitant variation of other metabolic markers Hollander and colleagues reported no significant change
in total cholesterol levels [28], a finding concordant withremains controversial. Previous studies had suggested
that the risk associated with hyperinsulinemia was largely our results in women. No change was noted for plasma
TG concentrations in both men and women, probablymediated by the concomitant dyslipidemia found in hy-
perinsulinemic men [39, 47–52]. However, we have re- because they were already in the normal range at base-
line. Conflicting results regarding the effects of steroidcently reported, among non-transplant patients, that the
risk of IHD related to hyperinsulinemia was largely inde- withdrawal on TG levels have been reported as either no
change [28] or increases in TG concentrations followingpendent of the concomitant dyslipidemic state [39].
Reported alterations in the plasma lipoprotein-lipid Pred tapering [29].
Plasma HDL cholesterol levels have been reportedprofile in RTX include increases in both total cholesterol
and TG levels and elevated LDL cholesterol and apo B to be low, normal or even slightly elevated after renal
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Fig. 2. Associations between triglyceride levels and LDL peak particle
size before () and after () prednisone withdrawal (A), and between
triglyceride changes and LDL peak particle diameter changes (B) in
response to prednisone withdrawal. In panel A, before withdrawal, r 
0.62, P  0.0007; after withdrawal, r  0.62, P  0.0008. In panel
B, r  0.51, P  0.008;
in patients with the nephrotic syndrome [55], and with
reduced liver CETP mRNA and plasma CETP in CETPFig. 1. Fasting plasma insulin (A) and apolipoprotein B (B) levels as
well as LDL peak particle size (C ) in renal transplant patients before transgenic mice [56]. In the present study, significantly
() and after () prednisone withdrawal. The number above bars reduced HDL cholesterol levels and higher plasma CETPindicates the relative change when significant changes were noted. *P
activity were observed in both genders after Pred taper-0.05; **P  0.005; ***P  0.0001; NS, non-significant.
ing. Similar results also were obtained by other groups
who reported significant reductions in HDL cholesterol
concentrations following Pred withdrawal [25, 28, 29].
transplantation [15–17, 20, 21]. Corticosteroids may raise The low CETP activity may explain the elevated HDL
HDL cholesterol levels by increasing apo A-I production cholesterol levels observed after renal transplantation
by the liver or/and via a mechanism decreasing CETP and the fall in HDL cholesterol concentrations following
activity. Indeed, corticosteroid therapy is associated with the withdrawal from steroids. HDLs are widely accepted
to play a protective role against the development ofa reduction in plasma CETP in both normal subjects and
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atherosclerosis [57, 58]. Whether these changes in HDL suggested that the measurement of fasting insulin and
apo B concentrations and LDL particle diameter couldcholesterol levels associated with Pred withdrawal affect
cardiovascular risk is not known, although it should be provide further information on the risk of IHD com-
pared to the estimated risk derived from the traditionalpointed out that values at the end of the follow-up period
remained in a normal range. Moreover, although the lipid variables. The fact that we were able to favorably
alter two of these three components (insulin and apo Bdecrease in HDL cholesterol produced an increase in
the cholesterol/HDL cholesterol ratio in men, it should levels) provides further support to the notion that we
need to go beyond the assessment of classical metabolicbe emphasized that this ratio was quite low (below 4.5)
and is still suggestive of a low cardiovascular disease risk risk factors such as lipoprotein-lipid levels to fully ap-
preciate the benefits of Pred withdrawal on IHD risk.[59]. Because a higher cholesterol/HDL cholesterol ratio
is a risk factor for cardiovascular disease [60, 61], the A significant reduction in body weight has been re-
ported following the withdrawal of corticosteroids [66],net effect of the changes in the lipoprotein-lipid profile
after Pred withdrawal on the risk of cardiovascular dis- a finding concordant with our results in our female pa-
tients. Corticosteroids promote appetite, insulin resis-ease has led to conflicting interpretations and remains
unresolved. We must keep in mind that no studies have tance and hyperinsulinemia, alterations that may pro-
mote caloric consumption and weight gain in treateddocumented an additional cardio-protective effect of in-
creasing HDL levels with Pred therapy. Indeed, we fre- patients [46]. Previous studies of RTX have suggested
that weight gain after transplantation is common, espe-quently observed unusually high levels of HDL among
these patients despite a well-established high prevalence cially among women [67, 68]. In this regard, pharmacoki-
netic studies have shown that women presented rela-of cardiovascular disease. Furthermore, members of CETP
deficiency families carrying very high levels of HDL (in tively low clearance of methylprednisone, suggesting that
higher exposure to steroids for any given dose could ac-the range often found among Pred-treated patients) are
not always protected, and they may even be at high risk count for a greater weight gain observed in these women
[69]. This biological variation among genders could, atfor cardiovascular disease [62]. Therefore, it is still not
clear whether elevated HDL levels carry the same least in part, explain differences found in our study be-
tween men and women regarding the effects of steroidcardio-protective effects in patients under Pred therapy
as compared to those without it or after withdrawal. withdrawal on body weight. For instance, the lowering
of body weight after Pred withdrawal in women mayThere is evidence that the dense LDL phenotype is
highly prevalent among IHD patients [63, 64]. This phe- have contributed to the greater reduction of fasting insu-
lin and apo B levels and the smaller reduction of HDLnotype also is associated with concomitant variations in
the plasma lipoprotein-lipid profile such as elevated TG cholesterol concentrations in women compared to men.
It also is important to point out that as body fat distribu-levels and reduced HDL cholesterol concentrations [32,
63, 65], which are predictive of an increased IHD risk. tion, especially visceral adipose tissue accumulation, has
been shown to be more closely related to hyperinsulin-However, in the present study, no improvement in the
LDL peak particle size was observed with Pred with- emia and to an atherogenic dyslipidemia than excess
fatness [70, 71], the possibility cannot be excluded thatdrawal. This finding is not surprising because TG levels
remained stable throughout the study. The significant women of the present study had decreased levels of vis-
ceral adipose tissue following Pred tapering as estimatednegative association between changes in TG concentra-
tions and changes in LDL peak particle size suggests by reduced waist girth. This issue will have to be exam-
ined in future studies.that individuals who decreased their TG concentrations
were those who showed an increase in LDL particle Despite new immunosuppressive protocols and a more
effective management of risk factors, cardiovascular dis-diameter.
A recent prospective study has emphasized the contri- ease remains a major cause of morbidity and mortality
after renal transplantation. A better understanding ofbution of a new atherogenic metabolic triad (hyperinsu-
linemia, elevated apo B levels and small, dense LDL the pathophysiology of the disease may lead to the devel-
opment of effective strategies for prevention and man-particles) as an important cluster of metabolic abnormal-
ities predictive of a substantially increased risk of IHD agement of coronary heart disease risk in RTX. Results
of the present study suggest that Pred tapering may have[35]. Indeed, it has been reported that the risk of devel-
oping IHD over five years in a sample of initially asymp- beneficial effects on plasma lipoprotein levels as well as
on components of the new atherogenic metabolic triad.tomatic middle-aged men was increased by more than
20-fold among individuals who were characterized by the Moreover, women may derive further benefits of steroid
withdrawal resulting from the concomitant loss of bodyatherogenic metabolic triad. Furthermore, the increased
risk was not significantly modified by adjustment for classi- weight and abdominal fat. However, the benefits of Pred
withdrawal have to be balanced against a higher risk ofcal lipid variables (LDL cholesterol, HDL cholesterol and
TG levels) [35]. Results of this prospective study thus kidney rejection. In well selected individuals, our anthro-
Lemieux et al: Prednisone withdrawal and the metabolic triad1846
nal transplantation: A 3-year follow-up. Transplant Proc 25:2178–pometric and metabolic data suggest that Pred with-
2179, 1993
drawal may have a beneficial impact on parameters that 19. Telci A, Salmayenli N, Aydin AE, et al: Serum lipids and apolipo-
protein concentrations and plasma fibronectin concentrations inhave been associated with an increased cardiovascular
renal transplant patients. Eur J Clin Chem Clin Biochem 30:847–risk in the overall population, and such changes may
850, 1992
contribute to decrease the cardiovascular disease risk in 20. Averna MR, Barbagallo CM, Sparacino V, et al: Follow-up of
lipid and apoprotein levels in renal transplant recipients. NephronRTX.
58:255–256, 1991
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